Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More
Listen to this article on the DDW Podcast: To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman spoke to Michael Altorfer (CEO of the Swiss Biotech Association), Jan Lucht (Head of Biotechnology, scienceindustries), Claude Joris (Secretary General, BioAlps), and Carole Delauney (Business Development Director… Read More
Ilya Pharma has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds (EudraCT 2021-000563-69). ILP100h has recently been assigned the INN name emilimogene sigulactibac by the World… Read More
A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More
In the aftermath of Covid-19, ambitious strategies for digital transformation are seen as a wise investment as life sciences organisations upgrade their capacities for managing clinical trials and the scientific and regulatory data they generate. This is the key overall finding of the second annual TMF Futures survey of over… Read More
Sinopia Biosciences has been awarded a grant from the National Institute of General Medical Sciences (NIGMS), as part of the National Institutes of Health, to further develop and validate their proprietary metabolomics-based high-throughput screening (HTS) platform with an initial focus on rare diseases. To date, Sinopia has received nearly $8… Read More
The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More
King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver… Read More
Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More
This paid-for advertorial by Twist Biopharma appeared in DDW Volume 22, Issue 3 – Summer 2021 By Dr Aaron Sato, Chief Scientific Officer, Twist Bioscience The efficiency of candidate antibody discovery pipelines is directly connected to the quality of the DNA library being screened. To reduce discovery timelines, researchers need… Read More
A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON… Read More
Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in… Read More
908 Devices has announced two data analysis partnerships to integrate with the REBEL, its first at-line fresh and spent cell media analyser for bioprocess labs. With the integration of leading data exploratory tool Sartorius’ SIMCA and Securecell’s Lucullus Process Information Management System (PIMS), users can turn REBEL data into deeper… Read More
Listen to this article on the DDW Podcast: Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE) is nothing new. While clinical trials have a significant part to play - and indeed remain the ultimate standard for… Read More
News round-up by DDW’s Megan Thomas for 28 June – 2 July This week in news The last year and a half has accelerated the virology scene at a pace that was previously unseen, and not exclusively for Covid-19. Vaccines continue to be an unquestionably important part of how we… Read More
Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of… Read More
